



Post Authorisation Assessments

CaniTrio Chewable Tablets for Dogs >2.5-5 kg Vm 42058/5126

06 February 2026	Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible
18 December 2025	Addition of a site where batch control or testing of the active substance takes place.
11 November 2025	Addition of indication 'Treatment of Angiostrongylus vasorum' with associated dosing information/precautions. Addition of indication 'Reduction in the risk of Dipylidium caninum via transmission by Ctenocephalides felis'.
29 July 2025	Replacement of a manufacturer responsible for batch release of the finished product.
01 May 2025	Changes in the manufacturing process of the active substance: - Other changes.
17 December 2024	Substantial changes in the updated version of the ASMF or the active substance part of the dossier. Substantial changes in the updated version of the ASMF or the active substance part of the dossier.
13 August 2024	Change in the synthesis of a non-pharmacopoeial excipient.
22 June 2024	Change in the address of a manufacturer of the finished product.
12 June 2024	Minor change to an approved test procedure for a starting material.
04 May 2024	Addition of a new specification parameter for a starting material.